Study on Belantamab Mafodotin with Standard Treatment for Relapsed-Refractory Multiple Myeloma

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of Multiple Myeloma.
• Have a performance status score of 0 to 2, indicating full activity or some restriction in strenuous activities.
• Previously treated with 1 to 2 lines of therapy and have shown disease progression.
• Have measurable disease based on specific medical tests.
• If previously had a stem cell transplant, it must have been over 100 days ago, with no active infections.
• All previous treatment side effects must be mild or resolved, except for hair loss.
• Must have adequate organ function based on lab tests.
• Must follow contraceptive guidelines to prevent pregnancy during the study.
• For the BPd arm, must have had prior treatment with lenalidomide for at least 2 cycles.

Exclusion Criteria

• Have active plasma cell leukemia.
• Have symptomatic amyloidosis or certain other conditions.
• Have another invasive cancer unless stable for 2 years and not receiving active treatment.
• Have allergies to belantamab mafodotin or similar drugs.
• Have had plasmapheresis within 7 days before starting the study.
• Have had an allogeneic stem cell transplant.
• Have had major surgery within 4 weeks before starting treatment, except for bone surgery.
• Have active bleeding issues.
• Cannot tolerate antiviral medications.
• Have certain eye conditions, except mild ones.
• Have had recent systemic anti-myeloma therapy or monoclonal antibody treatment.
• Have active kidney issues, except for certain conditions related to multiple myeloma.
• Have had prior BCMA-targeted therapy.
• Cannot wear contact lenses during treatment, except as directed by an eye specialist.
• Have uncontrolled HIV, hepatitis B, or C infections.
• Have significant liver issues or cardiovascular risks.
• For the BPd arm, cannot have had prior treatment with pomalidomide or recent blood clots.
• For the BVd arm, cannot be intolerant or resistant to bortezomib or have severe nerve pain.
• For the BKd arm, cannot be intolerant or resistant to carfilzomib, have certain heart issues, or need fluid drainage procedures.